EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation

Liang Zhao, Linjie Li, Chengcheng Wu, Hangkuan Liu, Geru Aa, Xiaozhi Chen, Zhiqiang Zhang, Nicholas W S Chew, Mark Y Y Chan, Ching-Hui Sia, Doreen Su-Yin Tan, Pengfei Sun und 2 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70650 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Liang Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Myocardial Infarction, Gastrointestinal Hemorrhage, Platelet Aggregation Inhibitors. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Tianjin Key Medical Discipline (Specialty) Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend co‐prescribing proton pump inhibitors (PPIs) with dual antiplatelet therapy (DAPT) after acute myocardial infarction (MI) to prevent gastrointestinal bleeding. Emerging evidence indicates that PPIs have distinct pharmacokinetic profiles, and their cardiovascular and bleeding effects may not represent a class effect.

Methods

We used electronic health record data from the Tianjin Health and Medical Data Platform to emulate target trials comparing effectiveness and safety of three commonly used PPIs in clinical practice. The effectiveness outcome was gastrointestinal bleeding, and the safety outcome was composite cardiovascular events. Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) between individual PPIs. We further applied XGBoost‐based prognostic models to assess treatment effect heterogeneity across strata of predicted baseline risk.

Results

Of 51 072 MI patients on DAPT, 22 671 were prescribed rabeprazole, 18 081 pantoprazole and 10 320 lansoprazole. During 1 year of follow‐up, both pantoprazole (HR, 1.05 [95% CI, 0.97–1.13]) and lansoprazole (HR, 0.99 [0.91–1.09]) showed comparable cardiovascular risk to rabeprazole, but pantoprazole was associated with an increased risk of recurrent MI (HR, 1.20 [1.07–1.35]). For gastrointestinal bleeding risk, lansoprazole showed lower risk (HR, 0.81 [0.70–0.93]) compared with rabeprazole. Results were robust in multiple sensitivity analyses, and treatment effect heterogeneity showed gastrointestinal benefits of lansoprazole increase with the rising baseline bleeding risk.

Conclusions

In patients with acute MI receiving DAPT, the three PPIs showed similar cardiovascular safety, while lansoprazole was associated with a lower risk of gastrointestinal bleeding. External validation is warranted to examine these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsMyocardial InfarctionGastrointestinal HemorrhagePlatelet Aggregation InhibitorsDual Anti-Platelet TherapyHumansPantoprazoleFemaleMaleAgedRabeprazoleLansoprazoleMiddle AgedTreatment OutcomeDrug Therapy, CombinationProportional Hazards Models

Stichwörter der Autor:innen

bleeding preventioncardiovascular outcomemyocardial infarctionproton pump inhibitors

Substanzen

Proton Pump InhibitorsPlatelet Aggregation InhibitorsPantoprazoleRabeprazoleLansoprazole

Autor:innen und Institutionen

  • Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
  • Yong Loo-Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Cardiology, National University Heart Centre, Singapore, Singapore.
  • Cardiovascular Research Institute, National University Health System, Singapore, Singapore.
  • Department of Pharmacy and Pharmaceutical Sciences, National University Singapore Faculty of Science, Singapore, Singapore.

ORCID-Profile: Xin Zhou

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Zhao, L., Li, L., Wu, C., Liu, H., Aa, G., Chen, X., Zhang, Z., Chew, N. W. S., Chan, M. Y. Y., Sia, C. H., Tan, D. S., Sun, P., Zhou, X., & Yang, Q. (2026). Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70650

Vancouver

Zhao L, Li L, Wu C, Liu H, Aa G, Chen X, et al. Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70650

BibTeX
@article{Zhao2026,
  author = {Zhao, Liang and Li, Linjie and Wu, Chengcheng and Liu, Hangkuan and Aa, Geru and Chen, Xiaozhi and Zhang, Zhiqiang and Chew, Nicholas W S and Chan, Mark Y Y and Sia, Ching-Hui and Tan, Doreen Su-Yin and Sun, Pengfei and Zhou, Xin and Yang, Qing},
  title = {Comparative effectiveness and safety of proton pump inhibitors after myocardial infarction on dual antiplatelet therapy: Insights from a target trial emulation},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70650}
}
Kostenlos starten →